Drug Trial Radar · NCT07086326
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
164
Planned (sponsor's estimate)
Start
Jul 31, 2025
Primary completion
Dec 30, 2026
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Yang Fan, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, multicenter phase II study. The trial plans to enroll 164 subjects with resectable stage IIA-IIIB (N2) NSCLC. Participants will be randomized 1:1 into either the ivonescimab plus chemotherapy or penpulimab plus chemotherapy treatment arm. After 3-4 cycles of neoadjuvant therapy, surgical resection will be performed. The primary objective is to compare the pathological complete response (pCR) rate assessed by local pathologists between ivonescimab-based and penpulimab-based chemo-immunotherapy regimens in the neoadjuvant treatment of resectable NSCLC.
Conditions
- NSCLC
- Neoadjuvant Therapy
- Immunotherapy
- AK112
- Bispecific Antibody
Interventions
Ivonescimab+ChemoDrug
Ivonescimab (AK112) + platinum-based doublet chemotherapy
Penpulimab+ChemoDrug
Penpulimab (AK105) + platinum-based doublet chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathologic Complete Response (pCR) RateTime frame: Within 1 month after surgery
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Hunan Cancer Hospital
Changsha, Hunan, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.